The API5 knockout A-549 polyclonal cells are a CRISPR/Cas9-edited polyclonal population of human lung adenocarcinoma epithelial cells engineered to disrupt the API5 gene. This pooled knockout model provides a heterogeneous collection of A-549 cells with gene-targeted loss-of-function modifications, enabling robust investigation of apoptosis regulation without the need for single-cell cloning. The polyclonal format maintains genetic diversity while ensuring functional ablation of API5 protein expression across the population, making it suitable for studies requiring pooled cell analysis.
The A-549 parental cell line was originally derived from a 58-year-old Caucasian male with lung adenocarcinoma and is characterized by a hypodiploid karyotype with a modal chromosome number of 66. As a model of type II alveolar basal epithelium, A-549 cells are extensively employed in respiratory disease research, drug metabolism and pharmacokinetics studies, and cancer biology. Their consistent growth characteristics and well-documented signaling network make them an ideal host for gene disruption experiments focused on apoptosis and tumor cell survival.
API5 (apoptosis inhibitor 5) functions as a critical suppressor of programmed cell death by directly binding and inhibiting the pro-apoptotic proteins PDCD6 and Acinus, thereby blocking the activation of caspase-9 and the subsequent cleavage of effector caspase-3. API5 operates downstream of FGF2/FGFR signaling and enhances survival signaling through the ERK pathway, supporting tumor cell viability under stress conditions. Expression of API5 is positively regulated by E2F transcription factors and serum growth factors, and it interacts with additional factors including APAF1 and XIAP to modulate the intrinsic apoptosis machinery. Disruption of API5 relieves suppression of PDCD6 and Acinus, leading to assembly of the apoptosome and caspase cascade activation, positioning API5 as a key node in the FGF2-ERK survival and caspase-dependent death pathways.
In the A-549 lung adenocarcinoma background, API5 plays a pivotal role in sustaining cell survival, particularly following growth factor deprivation or chemotherapeutic stress. The knockout of API5 sensitizes these tumor cells to apoptosis, offering a powerful system to dissect mechanisms of drug resistance, apoptotic threshold regulation, and the crosstalk between survival kinases and the caspases. This model is highly relevant for research into lung adenocarcinoma, non-small cell lung carcinoma, breast cancer, and cervical cancer, where API5 overexpression is often associated with poor prognosis and resistance to therapy.
Researchers can employ these polyclonal knockout cells in a wide range of assays, including Western blotting for caspase-3 cleavage to monitor apoptosis induction, MTT viability assays to assess drug sensitivity, and Annexin V flow cytometry for quantifying cell death. Co-immunoprecipitation experiments facilitate the study of API5 interactions with PDCD6 and Acinus, while caspase activity assays directly measure effector caspase function. Additionally, migration and invasion Transwell assays enable evaluation of API5’s role in metastatic behavior, and drug sensitivity screening can identify compounds that exploit the loss of API5-mediated survival signaling. For further technical details, assay protocols, or ordering information, please contact Ascent Research.
